Biosimilars/News

FDA accepts application for Mylan’s bevacizumab biosimilar

Biosimilars/News | Posted 06/03/2020

US-based drugmaker Mylan announced on 27 February 2020 that the US Food and Drug Administration (FDA) had accepted its application for its bevacizumab biosimilar (MYL 1402O).

Mylan launches anti-cancer biosimilar in the US

Biosimilars/News | Posted 21/02/2020

The US drug market receives a new oncology biosimilar as Mylan launches its trastuzumab biosimilar, Ogivri.

Mylan launches anti-cancer biosimilar in the US

Pfizer launching biosimilars in US and Japan but not in EU

Biosimilars/News | Posted 14/02/2020

In early 2020, pharma giant Pfizer announced that it was launching its rituximab biosimilar in Japan and that it would be launching three new biosimilars onto the US market.

Phase III trial started in China for eculizumab copy biological

Biosimilars/News | Posted 14/02/2020

Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) is starting a phase III clinical trial in China for a copy biological of Soliris (eculizumab), made by Alexion Pharmaceuticals (Alexion).

EMA approval for rituximab biosimilar Ruxience

Biosimilars/News | Posted 07/02/2020

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 31 January 2020 that it had recommended granting marketing authorization for the rituximab biosimilar Ruxience.

Rituximab biosimilar ABP 798 submitted to FDA

Biosimilars/News | Posted 07/02/2020

US-based biotech giant Amgen and its partner Allergan announced on 19 December 2019 that their rituximab biosimilar (ABP 798) had been successfully submitted to the US Food and Drug Administration (FDA) for review.

Teriparatide biosimilar Terossa approved in South Korea

Biosimilars/News | Posted 24/01/2020

South Korea-based Daewon Pharmaceutical has obtained regulatory approval to begin marketing and selling its teriparatide biosimilar in Korea.

Phase I trials started for aflibercept and ustekinumab biosimilars

Biosimilars/News | Posted 15/11/2019

Phase I trials have started for proposed biosimilars of aflibercept and ustekinumab.

South Korean biologicals company Alteogen has, according to clinicaltrials.gov, started a phase I trial for its candidate aflibercept biosimilar ALT-L9.

Bevacizumab and teriparatide biosimilars launched in Japan

Biosimilars/News | Posted 24/01/2020

Biosimilars for osteoporosis treatment teriparatide and for anticancer drug bevacizumab were launched in Japan in late 2019.

Samsung Bioepis and AffaMed to start trastuzumab trial in China

Biosimilars/News | Posted 17/01/2020

China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA) has granted approval for partners Samsung Bioepis and AffaMed Therapeutics (AffaMed) to start a phase III trial for their trastuzumab product, SB3.